INTEGRATING PRECISION MEDICINE PROTOCOLS
WITH MARKETED BIOTECH DRUGS

Biotech drugs are very expensive, costing $50,000 or more per patient per year. This could become a $1.5+ Trillion spending problem in the U.S. by 2025.

A significant majority of these drugs, however, provide excellent therapeutic response in 5-20% of treated patients.

The way we price, treat, and pay for biotech drugs must be redefined – the solutions that make sense and provide clarity to all stakeholders.

We have built a transformative platform to practice a patient-centric, precision medicine protocol with an objective of providing therapeutic, cost, and time advantages to payers and patients.

Equally, this platform provides significant advantages to pharma and biotech companies.

Treatment cum
Trial Protocol

  • All patients treated with biotech drugs are in patient-centric (N=1) assurance trial. The ‘clinical trial’ never truly ends.
  • The treatment model mimics a super large-sized, virtual clinical trial that could protect both payers from financial risk while enhancing the therapeutic value of these therapies – in each treated patient. This protocol is geared to treating up to 1+ million patients per disease and conducting in-house real-world evidence (RWE) trials.
  • It is operationalized through an integrated platform consisting of disease-specific precision medicine capabilities, virtual treatment and trial protocols, big data architecture, and machine learning.
  • It is administered by a third party – and thus avoids potential conflicts from pharma companies and payers.
  • This protocol can provide significant advantages in the following disease segments: Alzheimer’s, autoimmune and inflammatory disorders, select cancers particularly hematological malignancies, and rare diseases.

Proprietary Solutions

Patient-centric
Assurances

Ultra-large Treatment
& Trial Protocols
Disease-specific
Big Data Warehouse
Protocols sponsored
by a 3rd Party
3rd Party payers
can participate
plus

PAYER SPONSORED MODEL

Payers can be involved in pivotal, P-4 clinical trials

Disrupts the Big Pharma development model

plus

Middlemen not required

External PBMs, specialty pharmacies not required

This assurance-based model moves away from the current discount-coupon-rebate model

plus

Early entry of biosimilars and generics

Enables accelerated development and commercialization by getting around patent thickets

TEAM

img2

TEAM

CEO, Founder
Vice President, IP Counsel
Vice President, Drug Pricing

Board

Former U.S. Congressman
Ex-President and CEO, PhRMA
 

Strategic Advisory Board

Della Martin Chair of Psychiatry & Neuroscience
Keck School of Medicine of USC
Alzheimer's
Director
Luxembourg Center for Systems Biomedicine
Neuroinflammation and Alzheimer's
Co-inventor of Herceptin drug
Fellow, Kennedy Institute of Rheumatology
Lasker award (2019)
logo

3705 Haven Avenue
Menlo Park, CA 94025


+1 650-566-8344
info@klaritos.com